CN113694072A - Application of GGPP (gas-gas phase plasma) combination and allosteric activation of humanized FBP1 in preparation of anti-hepatocellular carcinoma drugs - Google Patents
Application of GGPP (gas-gas phase plasma) combination and allosteric activation of humanized FBP1 in preparation of anti-hepatocellular carcinoma drugs Download PDFInfo
- Publication number
- CN113694072A CN113694072A CN202110999973.0A CN202110999973A CN113694072A CN 113694072 A CN113694072 A CN 113694072A CN 202110999973 A CN202110999973 A CN 202110999973A CN 113694072 A CN113694072 A CN 113694072A
- Authority
- CN
- China
- Prior art keywords
- ggpp
- fbp1
- liver
- hepatocellular carcinoma
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001028852 Homo sapiens Fructose-1,6-bisphosphatase 1 Proteins 0.000 title claims abstract description 150
- 102100037181 Fructose-1,6-bisphosphatase 1 Human genes 0.000 title claims abstract description 133
- 206010073071 hepatocellular carcinoma Diseases 0.000 title claims abstract description 78
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 229940079593 drug Drugs 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 230000004913 activation Effects 0.000 title claims abstract description 9
- 230000003281 allosteric effect Effects 0.000 title claims abstract description 8
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims abstract description 54
- 210000004185 liver Anatomy 0.000 claims abstract description 51
- OINNEUNVOZHBOX-QIRCYJPOSA-K 2-trans,6-trans,10-trans-geranylgeranyl diphosphate(3-) Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP([O-])(=O)OP([O-])([O-])=O OINNEUNVOZHBOX-QIRCYJPOSA-K 0.000 claims abstract description 41
- OINNEUNVOZHBOX-XBQSVVNOSA-N Geranylgeranyl diphosphate Natural products [P@](=O)(OP(=O)(O)O)(OC/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)O OINNEUNVOZHBOX-XBQSVVNOSA-N 0.000 claims abstract description 41
- 102000023732 binding proteins Human genes 0.000 claims abstract description 34
- 108091008324 binding proteins Proteins 0.000 claims abstract description 34
- 230000000694 effects Effects 0.000 claims abstract description 33
- 210000004027 cell Anatomy 0.000 claims abstract description 32
- 229930186217 Glycolipid Natural products 0.000 claims abstract description 29
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 238000011161 development Methods 0.000 claims abstract description 26
- 230000002503 metabolic effect Effects 0.000 claims abstract description 23
- 201000007270 liver cancer Diseases 0.000 claims abstract description 19
- 102000004190 Enzymes Human genes 0.000 claims abstract description 17
- 108090000790 Enzymes Proteins 0.000 claims abstract description 17
- 230000004060 metabolic process Effects 0.000 claims abstract description 17
- 230000004110 gluconeogenesis Effects 0.000 claims abstract description 16
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 15
- 102000047994 human FBP1 Human genes 0.000 claims abstract description 13
- 230000009456 molecular mechanism Effects 0.000 claims abstract description 9
- 210000004738 parenchymal cell Anatomy 0.000 claims abstract description 7
- 230000005012 migration Effects 0.000 claims abstract description 5
- 238000013508 migration Methods 0.000 claims abstract description 5
- 230000001235 sensitizing effect Effects 0.000 claims abstract description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 229960002685 biotin Drugs 0.000 claims description 14
- 235000020958 biotin Nutrition 0.000 claims description 14
- 239000011616 biotin Substances 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 13
- 238000001261 affinity purification Methods 0.000 claims description 12
- 150000002632 lipids Chemical class 0.000 claims description 11
- 230000037361 pathway Effects 0.000 claims description 9
- 239000000523 sample Substances 0.000 claims description 8
- 238000004949 mass spectrometry Methods 0.000 claims description 7
- 102000027487 Fructose-Bisphosphatase Human genes 0.000 claims description 6
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 claims description 6
- 230000006682 Warburg effect Effects 0.000 claims description 5
- 230000034659 glycolysis Effects 0.000 claims description 5
- 230000002441 reversible effect Effects 0.000 claims description 5
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 claims description 4
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 claims description 4
- 102000013009 Pyruvate Kinase Human genes 0.000 claims description 4
- 108020005115 Pyruvate Kinase Proteins 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 17
- 238000000034 method Methods 0.000 abstract description 9
- 230000002440 hepatic effect Effects 0.000 abstract description 7
- 230000033228 biological regulation Effects 0.000 abstract description 6
- 230000009471 action Effects 0.000 abstract description 2
- 230000027455 binding Effects 0.000 description 36
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 17
- VWFJDQUYCIWHTN-UHFFFAOYSA-N Farnesyl pyrophosphate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-UHFFFAOYSA-N 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 150000003384 small molecules Chemical class 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 13
- 238000011813 knockout mouse model Methods 0.000 description 13
- 230000035772 mutation Effects 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 230000000638 stimulation Effects 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- 101000799318 Homo sapiens Long-chain-fatty-acid-CoA ligase 1 Proteins 0.000 description 10
- 102100033995 Long-chain-fatty-acid-CoA ligase 1 Human genes 0.000 description 10
- 102100039291 Geranylgeranyl pyrophosphate synthase Human genes 0.000 description 9
- 101000888406 Homo sapiens Geranylgeranyl pyrophosphate synthase Proteins 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000012795 verification Methods 0.000 description 9
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 8
- 230000035899 viability Effects 0.000 description 8
- 230000037430 deletion Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 7
- 238000010200 validation analysis Methods 0.000 description 7
- 101000677545 Homo sapiens Long-chain specific acyl-CoA dehydrogenase, mitochondrial Proteins 0.000 description 6
- 102100021644 Long-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 235000009200 high fat diet Nutrition 0.000 description 6
- 238000002703 mutagenesis Methods 0.000 description 6
- 231100000350 mutagenesis Toxicity 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 5
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 5
- 101150010122 FBP1 gene Proteins 0.000 description 5
- 108010033276 Peptide Fragments Proteins 0.000 description 5
- 102000007079 Peptide Fragments Human genes 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000009137 competitive binding Effects 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 4
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000037356 lipid metabolism Effects 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 3
- 238000003068 pathway analysis Methods 0.000 description 3
- 230000004850 protein–protein interaction Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002424 x-ray crystallography Methods 0.000 description 3
- WCWUXEGQKLTGDX-LLVKDONJSA-N (2R)-1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-pyrrolo[2,1-f][1,2,4]triazinyl]oxy]-2-propanol Chemical compound C1=C2NC(C)=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@H](O)C)=C1 WCWUXEGQKLTGDX-LLVKDONJSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 2
- -1 ACARDL Proteins 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101710167178 Geranylgeranyl pyrophosphate synthase 1 Proteins 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000007622 bioinformatic analysis Methods 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000004879 molecular function Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000002439 negative-stain electron microscopy Methods 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000013823 prenylation Effects 0.000 description 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 229940035936 ubiquinone Drugs 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100024853 Carnitine O-palmitoyltransferase 2, mitochondrial Human genes 0.000 description 1
- 101150073133 Cpt1a gene Proteins 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000988577 Homo sapiens 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- 101000859570 Homo sapiens Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 description 1
- 101000909313 Homo sapiens Carnitine O-palmitoyltransferase 2, mitochondrial Proteins 0.000 description 1
- 101000989606 Homo sapiens Cholinephosphotransferase 1 Proteins 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000010224 classification analysis Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 230000006127 geranylation Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 229940124303 multikinase inhibitor Drugs 0.000 description 1
- 238000003012 network analysis Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005109 two-dimensional liquid chromatography tandem mass spectrometry Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses application of GGPP (GGPP) combination and allosteric activation of humanized FBP1 in preparation of anti-hepatocellular carcinoma drugs. The amino acid sequence of the human FBP1 protein is shown as SEQID No. 1. The invention establishes a direct binding protein action network of GGPP in normal liver, and screens and verifies a plurality of GGPP binding proteins participating in regulation and control of hepatic glycolipid metabolism. The GGPP is specifically combined with FBP1 and up-regulates the enzyme activity of FBP1 to promote gluconeogenesis, and can inhibit the migration of liver parenchymal cells and liver cancer cells. The GGPP is coupled with glycolipid metabolic balance through sensitizing a target protein FBP1 of the GGPP, so that a molecular mechanism for generation and development of hepatocellular carcinoma is regulated, and the GGPP can be applied to treatment of the hepatocellular carcinoma. GGPP regulates the metabolic balance of hepatic glycolipids by specifically and directly combining with a target protein FBP1, and provides a new potential target, a medicine and a treatment method for treating HCC.
Description
Technical Field
The invention relates to the technical field of biology, in particular to application of geranylgeranyl pyrophosphate GGPP (GGPP) combination and allosteric activation of humanized FBP1 in preparation of an anti-hepatocellular carcinoma drug.
Background
Regulation of glycolipid metabolic homeostasis is the basis for maintaining the body's vital activities. In China, due to changes of life styles and dietary structures in recent decades, glycolipid metabolic modes of partial crowds are changed, and the incidence rate of metabolic syndromes such as obesity and diabetes is remarkably increased. Liver plays the first place as a central organ of metabolism, and chronic Liver diseases such as Non-alcoholic fatty Liver disease (NAFLD) and hepatic fibrosis (Liver fibrosis) are caused by long-term disturbance of glycolipid metabolism. Recent research results show that in addition to viral hepatitis and alcoholic liver diseases, metabolic syndrome, NAFLD and other chronic liver diseases are also important causes of primary liver cancer. Meanwhile, by controlling glycolipid metabolism of cancer cells, prevention and treatment of cancer by specifically blocking energy sources of cancer cells using various strategies are also receiving increasing attention. Therefore, glycolipid metabolic homeostasis plays an important role in the development, prevention, early diagnosis and treatment of primary liver cancer.
Hepatocellular carcinoma (HCC), the major type of primary liver cancer, is one of the most common in vivo malignancies worldwide and one of the most common causes of tumor-related death. In addition to surgical treatment, Sorafenib (Sorafenib), a multi-kinase inhibitor, is the only drug approved by many countries for systemic treatment of advanced HCC in patients with advanced liver cancer, but is expensive, has special adverse reactions, and leaves doubt on the effectiveness of different patients. In addition, in the development of new drugs, clinical tests of other molecular targeting preparations such as Sunitinib (Sunitinib), Brivanib (Brivanib) and linivanib (linifib) for treating liver cancer all obtain a series of negative results. The new application of old drugs is a new trend of drug research and development due to the fact that research and development time, cost and clinical application period can be greatly shortened in the process of drug research and development with high investment and high risk. As a clinical most common lipid-lowering prescription drug, the population of Statins (Statins) is wide, and the drug is mainly applied to the treatment and prevention of hyperlipidemia and various cardiovascular diseases accompanied by metabolic syndrome. Recent large clinical statistics show that Statins can reduce the risk of death in patients with various cancers such as HCC, suggesting the possibility of HCC as a new indication for Statins. However, there is still uncertainty about the role of statins in HCC prevention and treatment. This may be related to the fact that statins inhibit the hydroxymethyl glutaryl-coenzyme a reductase (3-hydroxy-3-methylglutaryl-CoA reductase, HMGCR) located upstream of the mevalonate pathway, leading to the synthesis of a number of metabolic small molecules downstream thereof with important biological functions, such as Farnesyl pyrophosphate (FPP), Squalene (Squalene), Cholesterol (Cholesterol), Geranylgeranyl pyrophosphate (GGPP) and Ubiquinone (Ubiquinone), which are hindered (as shown in fig. 1).
The body's response to these metabolic small molecule deletions is extremely complex, which may be one of the important reasons why statins have significant differences in their therapeutic effects on different cancer types and even on different individual patients. The function of the small molecules in the metabolic pathway of mevalonate in the occurrence and development of HCC is clarified, and the application of statins in HCC treatment and the further development of related treatment schemes are of great significance. FIG. 1 is a diagram of the mevalonate pathway.
Among them, Geranylgeranyl pyrophosphate (GGPP) is one of important metabolic small molecules downstream of mevalonate pathway, and is another important product of Farnesyl pyrophosphate (FPP) besides cholesterol (as shown in fig. 1). FPP and GGPP have been reported to have main functions of participating in important protein lipid acylation modification, namely prenylation modification, as substrates, and the positions and activities of certain specific proteins on a membrane system are changed by respectively changing the hydrophobicity of the specific proteins so as to regulate and control a downstream signal path, thereby playing specific functions.
Geranylgeranyl pyrophosphate synthase 1(Geranylgeranyl pyrophosphate synthase 1, GGPPS1) is a synthase responsible for catalyzing the conversion of FPP to GGPP in vivo. The laboratory utilizes Ggpps1 specific knockout mice in different organ tissues to research the influence of the relative change of FPP and GGPP levels on the body functions. The explanation of the Ggpps1 knockout mouse phenotype focuses on the change of the prenylation modification mode of a protein after the balance of FPP/GGPP is disrupted, namely geranylation modification is deleted, and the downstream signal path is changed due to the excessive farnesylation activation of a specific protein, so that a series of phenotypes, such as adult mouse cardiac hypertrophy, male mouse reproductive disorder, female mouse oocyte developmental disorder and the like, appear. Analysis of skeletal muscle specificity Ggpps1 knockout heterozygote mice shows that the GGPPS1 deletion triggers high fat-induced systemic insulin resistance, and the GGPPS1 is proved to be involved in lipid metabolism regulation. Research on liver-specific Ggpps1 knockout mice shows that the Ggpps1 knockout reduces the level of GGPP in the liver of the mice and also reduces fat accumulation caused by high-fat food in the liver, and the GGPP is suggested to have an important regulating effect on the glycolipid metabolic balance of the liver. More importantly, liver-specific Ggpps1 knockout mice are more prone to develop primary liver cancer when subjected to DEN chemical mutagenesis; the clinical detection of liver cancer samples of HCC patients shows that the expression level of the synthetase GGPPS1 of GGPP is positively correlated with the malignancy degree of HCC, and the HCC patients with high expression of GGPPS1 have better prognosis, which indicates that GGPPS1 and GGPP can be compensated and up-regulated in the HCC exacerbation process to protect the liver. Meanwhile, Metadrug software analysis of Keruiwei-an also showed that GGPP had significant antitumor activity. These results suggest that GGPP plays an important role in regulation of hepatic glycolipid metabolism and development of liver cancer, but the direct target protein regulated by GGPP and the corresponding action mechanism are not known at present.
FBP1 is a key rate-limiting enzyme in gluconeogenesis and has also been shown to be an important oncostatin. There are many studies reporting that deletion, mutation and reduced expression of FBP1 may cause the occurrence and development of various cancers such as hepatocellular carcinoma, renal clear cell carcinoma, non-small cell lung cancer, breast cancer, etc. In HCC, the deletion or reduction of FBP1 can influence Warburg effect to cause glycolipid metabolic disorder and abnormal accumulation of lipid, provide a large amount of substance and energy for cancer cells, and accelerate the occurrence and development of HCC. Statistical data also indicate that patients with high expression levels of FBP1 in HCC have a significantly better prognosis, making FBP1 a potential prognostic marker for HCC.
At present, the application of geranylgeranyl pyrophosphate GGPP (GGPP) in combination and allosteric activation of human FBP1 in preparation of anti-hepatocellular carcinoma drugs is lacked.
Disclosure of Invention
In order to solve the defects of the prior art, the invention provides an application of geranylgeranyl pyrophosphate GGPP (GGPP) combination and allosterically activated human FBP1 in preparation of an anti-hepatocellular carcinoma drug.
In order to achieve the purpose of the invention, the technical scheme adopted by the invention is as follows: the invention discloses an application of geranylgeranyl pyrophosphate GGPP (GGPl) in combination and allosteric activation of humanized FBP1 in preparation of anti-hepatocellular carcinoma drugs, wherein the chemical formula of geranylgeranyl pyrophosphate GGPP is shown as a formula (I):
the amino acid sequence of the human FBP1 protein is shown as SEQID No. 1.
Further, the geranylgeranyl pyrophosphate GGPP specifically binds to FBP1 and up-regulates the enzymatic activity of FBP1 to promote gluconeogenesis and inhibit the migration of parenchymal liver cells and liver cancer cells.
Furthermore, the geranylgeranyl pyrophosphate GGPP is coupled with glycolipid metabolic balance by sensitizing a target protein FBP1 of the geranylgeranyl pyrophosphate GGPP, so as to regulate the molecular mechanism of the occurrence and development of hepatocellular carcinoma and act on the hepatocellular carcinoma.
Furthermore, a GGPP probe with a Biotin label is synthesized, a Biotin-streptavidin affinity purification system is utilized to enrich GGPP binding protein in primary liver parenchymal cells of mice, mass spectrum detection is carried out, and a plurality of GGPP potential target proteins related to glycolipid metabolism, fructose-1, 6-diphosphatase 1 in a gluconeogenesis pathway, liver pyruvate kinase in a glycolysis pathway and carnitine palmitoyltransferase 1 involved in lipid oxidation are screened out.
Further, the GGPP specifically binds to FBP1 and up-regulates the enzyme activity of FBP1 to promote gluconeogenesis and reverse the Warburg effect of tumors so as to inhibit the occurrence and development of various tumors.
Furthermore, the anti-tumor drug is an anti-hepatocellular carcinoma drug.
Has the advantages that: the invention adopts a high-flux chemical proteomics method to establish a direct binding protein action network of geranylgeranyl pyrophosphate GGPP in normal liver for the first time, and screens and verifies a plurality of GGPP binding proteins participating in regulation and control of liver glycolipid metabolism. From a plurality of aspects such as molecular level, cell level, animal model and clinical case, the GGPP regulates and controls the metabolic balance of the hepatic glycolipid by the specific direct combination with the target protein FBP1, thereby regulating the molecular mechanism of the generation and development of HCC and providing a new potential target, a drug and a treatment method for the treatment of HCC.
Compared with the prior art, the invention has the following advantages: according to further research on interaction of geranylgeranyl pyrophosphate GGPP and FBP1, the GGPP can be specifically combined with FBP1 and can be used for up-regulating enzyme activity of FBP1 to promote gluconeogenesis and inhibiting migration of parenchymal hepatic cells and liver cancer cells; by means of molecular docking, FBP1 mutant and cryo-electron microscopy experiments, the invention confirms the binding mode of GGPP and FBP1, key sites and the mechanism of allosterically activating FBP 1. The molecular mechanism of the GGPP for regulating the occurrence and development of the hepatocellular carcinoma by sensitizing the target protein FBP1 coupled glycolipid metabolic balance of the GGPP is deeply clarified, and potential drugs and targets are provided for the treatment of the hepatocellular carcinoma.
Drawings
FIG. 1 is a diagram of the mevalonate pathway.
FIG. 2 is a Biotin-labeled Biotin-GGPP (BGPP) molecular diagram of the present invention.
FIG. 3 is a technical route diagram of the metabolic small molecule GGPP target protein screening method of the invention.
FIG. 4 is an affinity purification diagram of the metabolic small molecule GGPP target protein of the invention.
FIG. 5 is a bioinformatic analysis of the GGPP potential direct binding protein of the present invention. Gene Ontology analysis of GGPP binding protein, including biological processes, molecular functions and cellular component analysis; KEGG pathway analysis of ggpp binding protein; functional classification of ggpp binding proteins; analysis of protein-protein interaction networks of key enzymes regulating carbohydrate metabolism and lipid metabolism in ggpp-binding proteins.
FIG. 6 is a table of FPP/GGPP ratios of liver-specific Ggpps1 knockout mice of the invention. A. The ratio of FPP/GGPP and FOH/GGOH of primary liver parenchymal cells of a liver-specific Ggpps1 knockout mouse is changed; B. wild type and liver-specific Ggpps1 knockout liver morphology under normal diet and high fat induction; C. HE staining of liver sections from wild-type and liver-specific Ggpps1 knockouts, vacuoles or lipid droplets shown in the WT HFD group; D. liver sections from wild-type and liver-specific Ggpps1 knockouts were oil red stained, and red dots indicated lipid droplets in the liver.
FIG. 7 shows peptide fragments and secondary spectra of GGPP-binding protein FBP1 identified by affinity purification mass spectrometry of the invention. A. The peptide condition of GGPP binding protein FBP1 identified by two times of affinity purification mass spectra; b. fbp1 peptide DFDPAINEYLQR2+ (m/z 740.85) secondary spectrum.
FIG. 8 shows Western blot and MST verification of a plurality of GGPP-binding proteins of the present invention. Western blot verification of GGPP binding proteins such as FBP1, ACARDL, ACSL1 and the like; validation of binding of fbp1, ACADL and ACSL1 to GGPP; validation of fbp1, ACADL and ACSL1 in combination with BGPP.
FIG. 9 shows the competitive binding experiment of GGPP-binding protein FBP1 of the present invention and the verification of SPR and BLI. Competitive binding experiments for the ggpp binding protein FBP 1; SPR verification of ggpp and FBP1 binding; validation of BLI binding of ggpp and FBP 1.
FIG. 10 is a graph showing that the GGPP of the invention binds to FBP1 and then significantly up-regulates the enzyme activity of FBP 1. Ggpp binding to FBP1 did not affect FBP1 homotetramer formation; ggpp and FBP1 binding significantly up-regulated FBP1 enzyme activity, whereas FPP had no activating effect.
FIG. 11 is a graph showing structural changes of FBP1 tetramer after GGPP binds to FBP1 by negative staining electron microscopy of the present invention. Negative staining electron microscope integral results of FBP1 tetramer after addition of FBP1 and GGPP; collecting FBP1 and GGPP-FBP1 particles with different conformations by using a negative dye electron microscope after C-D magnification; E-F3D reconstruction of the particle conformations of negative stain electron microscopy FBP1 and GGPP-FBP 1; g-j.3d reconstitution revealed conformational and turn changes in FBP1 tetramer upon GGPP binding.
FIG. 12 is a graph of the central cavity of an FBP1 tetramer in which GGPP binding is revealed by X-ray crystallography according to the present invention.
FIG. 13 is a diagram showing that the mutation at FBP1-R50 site of the present invention inhibits the activity of FBP1 in inhibiting hepatoma cells in response to GGPP stimulation. R50 reduces the ability of FBP1 to inhibit the viability and proliferation of hepatoma cells Huh7 in response to GGPP stimulation; the mutation of C-D.R50 reduces the ability of FBP1 to inhibit the viability and proliferation of hepatoma cells HepG2 in response to GGPP stimulation.
FIG. 14 is a graph showing that the GGPP-binding site mutation of human FBP1 protein of the invention inhibits the activity of FBP1 enzyme in response to GGPP stimulation. Ggpp binding site mutations do not affect FBP1 homotetramer formation; GGPP binding site mutations inhibit FBP1 enzymatic activity in response to GGPP stimulation.
FIG. 15 is a graph showing that GGPP precursor GGOH of the present invention can reverse the occurrence and development of hepatocellular carcinoma in mice. A. High fat diet and chemical mutagenesis to make a time line of mouse primary hepatocellular carcinoma model; B. normal control group, high fat diet and chemical mutagenesis mice primary hepatocellular carcinoma group and reversal after GGOH anaplerosis; the degree of malignancy of hepatocellular carcinoma in three groups of mice in C-E.B was compared and statistical analysis of the number and volume of tumors was performed.
FIG. 16 is a graph showing that GGPP treatment of the present invention significantly inhibited the viability and proliferation of hepatoma cells. GGPP treatment obviously inhibits the activity and proliferation of liver cancer cells Huh 7; GGPP treatment obviously inhibits the activity and proliferation of liver cancer cells HepG 2.
Detailed Description
In order to facilitate an understanding of the invention, the invention will now be described more fully hereinafter with reference to the accompanying drawings, in which several embodiments of the invention are shown, but which may be embodied in different forms and not limited to the embodiments described herein, but which are provided so as to provide a more thorough and complete disclosure of the invention.
The invention discloses an application of geranylgeranyl pyrophosphate GGPP (GGPl) in combination and allosteric activation of humanized FBP1 in preparation of anti-hepatocellular carcinoma drugs, wherein the chemical formula of geranylgeranyl pyrophosphate GGPP is shown as a formula (I):
the amino acid sequence of the human FBP1 protein is shown as SEQID No. 1.
The geranylgeranyl pyrophosphate GGPP is specifically combined with FBP1 and up-regulates the enzyme activity of FBP1 to promote gluconeogenesis and inhibit the migration of liver parenchyma cells and liver cancer cells.
The geranylgeranyl pyrophosphate GGPP is coupled with glycolipid metabolic balance by sensitizing a target protein FBP1 of the geranylgeranyl pyrophosphate GGPP, so as to regulate a molecular mechanism for the occurrence and development of hepatocellular carcinoma and act on the hepatocellular carcinoma.
Synthesizing a GGPP probe with a Biotin label, enriching GGPP binding protein in primary liver parenchymal cells of a mouse by using a Biotin-streptavidin affinity purification system, and performing mass spectrometry to screen out a plurality of GGPP potential target proteins related to glycolipid metabolism, fructose-1, 6-diphosphatase 1 in a gluconeogenesis pathway, liver pyruvate kinase in a glycolysis pathway and carnitine palmitoyltransferase 1 involved in lipid oxidation.
The GGPP is specifically combined with FBP1 and up-regulates the enzyme activity of FBP1 to promote gluconeogenesis and reverse the Warburg effect of tumors so as to inhibit the occurrence and development of various tumors.
The anti-tumor drug is an anti-hepatocellular carcinoma drug.
Example 1
A Biotin-labeled GGPP probe is used for enriching GGPP binding protein in primary Liver parenchyma cells of mice by using a Biotin-streptavidin affinity purification system and performing mass spectrometry, so that a plurality of GGPP potential target proteins related to glycolipid metabolism are screened, such as Fructose-1, 6-diphosphatase 1(Fructose-1, 6-biphosphatase, FBP1) in a gluconeogenesis pathway, Liver Pyruvate Kinase (LPK) in a glycolysis pathway, Carnitine palmitoyltransferase 1 (CPT 1) involved in lipid oxidation and the like. Among them, FBP1 has attracted attention due to its significance in binding to GGPP (as shown in fig. 5-8), its important role in regulation of glycolipid metabolism, and its association with various cancers.
1. Establishing a technical route for enriching and identifying the metabolic small molecule GGPP direct binding protein
1.1 design and Synthesis of Biotin-GGPP Probe
In order to enrich the liver for proteins that bind directly to GGPP, the present invention synthesizes biotin-tagged GGPP probes (BGPP, FIG. 2). In the BGPP molecule, biotin is added at the C3 position of the long-chain carbon skeleton of GGPP molecule with a biotin label, so as to ensure the flexibility of the front hydrophobic long chain and the rear pyrophosphate of GGPP and expose the interaction with the binding protein of GGPP. FIG. 2 is a Biotin-labeled Biotin-GGPP (BGPP) molecular diagram of the present invention.
The chemical formula of the GGPP (Chinese name: geranylgeranyl pyrophosphate) is shown as a formula (I):
1.2 general metabolic small molecule or drug small molecule target protein screening technical route
The invention establishes a general metabolic small molecule or drug small molecule target protein screening technical route (figure 3). To identify target proteins in the liver that bind directly to and are regulated by GGPP, we synthesized biotin-tagged GGPP molecules and treated isolated, cultured primary hepatocytes of 8-week-old C57BL/6J male mice, respectively, with biotin and GGPP alone as controls. After total protein is extracted from the lysed cells, GGPP binding protein is purified through streptavidin magnetic bead affinity, mass spectrometry is carried out by using 2D LC-MS/MS, and then a possible GGPP interaction protein group in primary parenchymal hepatocytes of adult mice is obtained by combining unlabeled proteomics quantification and biological information analysis based on spectrogram number calculation. Through the technical route, the invention can screen the direct binding protein of important metabolic small molecules or drug small molecules in human bodies or cells, and provides targets and theoretical basis for explaining the biological activity and the acting molecular mechanism of the small molecules. FIG. 3 is a technical route for screening a metabolic small molecule GGPP target protein; FIG. 4 is an affinity purification diagram of the metabolic small molecule GGPP target protein of the invention.
In the invention, primary hepatic parenchymal cells of an 8-week-old C57BL/6J male mouse are separated and are divided into three parts to be cultured respectively. When experimental grouping was performed with addition of small molecule drugs, two negative controls were set: separately cultured primary hepatocytes of mice were treated with a (Biotin & GGPP) addition group and a (BGPP & 8-fold GGPP) competition group, respectively, and a BGPP addition group, respectively. After 4 hours of drug addition, three groups of mouse primary hepatocytes were lysed to extract total protein (Input) and affinity purified by addition of streptavidin magnetic beads to obtain potential GGPP Acting Protein (AP) in adult mouse primary hepatocytes. After silver staining is carried out on the binding protein obtained by affinity purification of the Biotin-GGPP, a plurality of obvious difference bands are found in the Biotin-GGPP group compared with the Biotin group (figure 4), which indicates that the GGPP may indeed have specific binding protein. Therefore, the invention carries out further LC-MS/MS mass spectrometry analysis on the proteins. FIG. 5 is a bioinformatic analysis of GGPP potential direct binding proteins of the present invention; gene Ontology analysis of GGPP binding protein, including biological processes, molecular functions and cellular component analysis; KEGG pathway analysis of ggpp binding protein; functional classification of ggpp binding proteins; analysis of protein-protein interaction networks of key enzymes regulating carbohydrate metabolism and lipid metabolism in ggpp-binding proteins.
After database search is carried out on the mass spectrum raw data, 259 and 479 proteins are respectively detected by a Biotin control group and a Biotin-GGPP treatment group. And integrating the data of the two groups for performing Label Free relative quantitative comparison, and obtaining 211 potential GGPP binding proteins by taking the standards that the relative abundance is up-regulated by more than 1.5 times in a Biotin-GGPP group compared with a Biotin control group and the number of detected peptide segments is more than 1. Bioinformatic analyses of these 211 proteins, including Gene Ontology analysis (fig. 5A-C), KEGG Pathway analysis (fig. 5D), protein functional classification analysis (fig. 5E) and protein-protein interaction network analysis (fig. 5F), showed the results: these proteins are involved in a large number of various metabolic processes, notably in fatty acid metabolism and the glycolysis/gluconeogenesis pathway. These glycolipid metabolism-associated proteins such as CPT1 alpha and FBP1 can be candidate proteins for subsequent study on the mechanism of GGPP in regulating liver metabolic diseases and hepatocellular carcinoma (Table 1). Key enzymes regulating hepatic glycolipid metabolism in the GGPP direct binding proteins of the invention are shown in table 1:
test example 1
Construction and phenotypic analysis of liver-specific Ggpps1 knockout mice
In order to research the influence of GGPP deletion on liver lipid metabolism, the invention successfully constructs Ggpps1-/-Mx1-Cre liver-specific induced knockout mice and associated phenotypic analysis was performed. In liver-specific Ggpps1 knockout mouse liver primary cells, metabonomic mass spectrometric detection shows that the ratios of FPP/GGPP and FOH/GGOH are remarkably increased (FIG. 6A), and the reduction of GGPP content and the increase of FPP content remarkably inhibit the accumulation of Triglyceride (TG) in liver-specific Ggpps1 knockout mice, so that knockout mice are not sensitive to high fat diet induction and do not have obvious fatty liver phenotype (FIGS. 6B-D). FIG. 6 shows FPP/GGPP ratios and phenotypes of liver-specific Ggpps1 knockout mice of the present invention; A. the ratio of FPP/GGPP and FOH/GGOH of primary liver parenchymal cells of a liver-specific Ggpps1 knockout mouse is changed; B. wild type and liver-specific Ggpps1 knockout liver morphology under normal diet and high fat induction; C. HE staining of liver sections from wild-type and liver-specific Ggpps1 knockouts, vacuoles or lipid droplets shown in the WT HFD group; D. liver sections from wild-type and liver-specific Ggpps1 knockouts were oil red stained, and red dots indicated lipid droplets in the liver.
Test example 2
GGPP regulates and controls hepatic glycolipid metabolism to participate in the occurrence and development of hepatocellular carcinoma by combining with FBP1
FBP1 is a key rate-limiting enzyme in gluconeogenesis and has also been shown to be an important oncostatin. There are many studies reporting that deletion, mutation and reduced expression of FBP1 may cause the occurrence and development of various cancers such as hepatocellular carcinoma, renal clear cell carcinoma, non-small cell lung cancer, breast cancer, etc. In stem cell cancer HCC, the deletion or reduction of FBP1 can influence Warburg effect to cause glycolipid metabolic disorder and abnormal accumulation of lipid, provide a large amount of substances and energy for cancer cells, and accelerate the occurrence and development of HCC. Statistical data also indicate that patients with high expression levels of FBP1 in HCC have a significantly better prognosis, making FBP1 a potential prognostic marker for HCC.
Clinically, the expression level of the synthetase GGPPS1 of GGPP is positively correlated with the malignancy degree of HCC in HCC patient samples, and the HCC patient with high expression of GGPPS1 has better prognosis, which suggests that GGPPS1 and GGPP may be up-regulated in the HCC exacerbation process by compensation to protect the liver. It is speculated that GGPP is involved in the generation and development of HCC by binding FBP1 and up-regulating its activity to influence glycolipid metabolic balance. Therefore, the invention clarifies the molecular mechanism that GGPP regulates glycolipid metabolism balance through the specific direct combination with the target protein FBP1 of GGPP, thereby regulating the generation and development of HCC, and provides a new potential target, a medicine and a treatment method for the treatment of HCC from a plurality of aspects such as molecular level, cell level, animal model and clinical case.
Secondary spectrum of 1 GGPP binding protein FBP1 peptide fragment
In two affinity purification repeated experiments with BGPP as a probe, the human FBP1 protein is identified in the invention, the number of peptide fragments identified by protein mass spectrum is 7 and 5 respectively, and the overall coverage rate of the human FBP1 protein is 28.7% and 26% respectively (FIG. 7A). FBP1 peptide DFDPAINEYLQR2+The B-series and y-series ion peaks of the (m/z-740.85) secondary spectrum perfectly covered the entire peptide fragment (fig. 7B), suggesting without doubt that the present invention indeed identified FBP1 in BGPP binding proteins. FIG. 7 shows peptide fragments and secondary spectra of GGPP-binding protein FBP1 identified by affinity purification mass spectrometry according to the present invention; A. the peptide condition of GGPP binding protein FBP1 identified by two times of affinity purification mass spectra; FBP1 peptide DFDPAINEYLQR2+(m/z-740.85) secondary spectrum.
Western blot and MST verification of 2 GGPP binding protein FBP1
Through Western blot, the invention verifies that FBP1, ACADL and ACSL1 in BGPP binding protein are as follows: the AP samples from the BGPP group contained significantly enriched FBP1, ACADL and ACSL1 proteins compared to the negative control group of Biotin & GPPP (fig. 8A). Meanwhile, in order to further verify the direct binding of glycolipid metabolism-related proteins such as FBP1, ACADAL and ACSL1 and GGPP, the fusion protein with an EGFP label is expressed and purified by using an escherichia coli prokaryotic expression system, and then micro-calorimetric electrophoresis (MST) analysis is carried out, so that the FBP1, ACADAL and ACSL1 proteins can be specifically and directly bound with GGPP, and the dissociation constant KD value of the combination of FBP1 and GGPP is 250nM (FIGS. 8B-C). FIG. 8 is a Western blot and MST validation graph of a plurality of GGPP-binding proteins of the invention; western blot verification of GGPP binding proteins such as FBP1, ACARDL, ACSL1 and the like; validation of binding of fbp1, ACADL and ACSL1 to GGPP; validation of fbp1, ACADL and ACSL1 in combination with BGPP.
Competitive binding experiments with 3 GGPP binding to FBP1, SPR and BLI
FBP1 as a candidate molecule for subsequent biological function studies was further subjected to binding verification of GGPP in various ways. The GGPP competitive binding experiments show that the binding of BGPP to human FBP1 protein decreases in a dose-dependent manner when high doses of free GGPP molecules are present. When the concentration of free GGPP reached 40 μ M (8-fold that of the BGPP probe), binding of BGPP and FBP1 was almost completely disrupted, demonstrating that BGPP specifically binds directly to human FBP1 protein (fig. 9A). Experiments such as Surface Plasmon Resonance (SPR) (fig. 9B) and molecular interaction (BLI) (fig. 9C) also showed that FBP1 recombinant protein purified from e.coli can specifically bind to GGPP in vitro. Dissociation constant K of FBP1 and GGPP binding detected by SPRDThe value was 262nM (FIG. 9B). FIG. 9 shows the competitive binding assay of the GGPP-binding protein FBP1 of the invention and the verification of SPR and BLI; competitive binding experiments for the ggpp binding protein FBP 1; SPR verification of ggpp and FBP1 binding; validation of BLI binding of ggpp and FBP 1.
4 GGPP combines to up-regulate the enzyme activity of FBP 1; FIG. 10 significant upregulation of FBP1 enzymatic activity following binding of GGPP to FBP 1; ggpp binding to FBP1 did not affect FBP1 homotetramer formation; ggpp and FBP1 binding significantly up-regulated FBP1 enzyme activity, whereas FPP had no activating effect.
FBP1 is a key rate-limiting enzyme in gluconeogenesis. Therefore, it is important to research whether the GGPP combined with FBP1 influences the enzyme activity. To elucidate the biological function of direct binding of GGPP to FBP1, the present invention further examined the effect of GGPP on FBP1 activity. In vitro experiments demonstrated that GGPP did not affect FBP1 homotetramer formation (fig. 10A), but could significantly up-regulate FBP1 activity in a dose-dependent manner (fig. 10B), whereas FPP, which is structurally similar to GGPP, did not, indicating that GGPP specifically binds FBP1 and regulates its activity. The effectiveness of the detection system is proved by the fact that the activity of FBP1 is reduced in a dose-dependent manner by using AMP as an FBP1 activity inhibitor which is reported in the literature.
Characterization of the binding pattern of 5 GGPP and FBP 1; FIG. 11 is a negative stain electron micrograph showing the structural change of FBP1 tetramer after GGPP binds to FBP 1; negative staining electron microscope integral results of FBP1 tetramer after addition of FBP1 and GGPP; collecting FBP1 and GGPP-FBP1 particles with different conformations by using a negative dye electron microscope after C-D magnification; E-F3D reconstruction of the particle conformations of negative stain electron microscopy FBP1 and GGPP-FBP 1; g-j.3d reconstitution revealed conformational and turn changes in FBP1 tetramer upon GGPP binding.
In order to clarify the molecular mechanism of activating FBP1 activity by GGPP, the invention analyzes the conformational change of the FBP1 homologous protein tetramer after GGPP is added by a cryo-electron microscope. The results show that GGPP binding decreases the angle between the upper and lower FBP1 dimers in the FBP1 tetramer, resulting in a deflection of around 6 degrees (FIG. 11). After GGPP is added, the relative positions of two dimers in FBP1 tetramer can be better stabilized, and the relative angle between the two dimers is reduced. Further X-ray crystallography results indicated that GGPP molecules specifically bind to the central cavity of FBP1 tetramer, and FBP1 amino acid residues that directly interact with it include R50, S46, P189 and a190, etc. (fig. 12). This binding of GGPP acts like a "keeper" that blocks the rotation of the upper and lower dimers in FBP1 tetramer from being converted to the inactive R state, thereby leaving FBP1 tetramer largely in the active T state, up-regulating the activity of FBP 1. FIG. 12 is a graph of the central cavity of an FBP1 tetramer in which GGPP binding is revealed by X-ray crystallography according to the present invention.
According to the results of the above structural experiments, the present inventors constructed mutants of FBP1 and observed their ability to form FBP1 tetramer and changes in enzyme activity. The results showed that mutation of the GGPP binding site of the human FBP1 protein hardly affected FBP1 tetramer formation (fig. 14A), but significantly inhibited FBP1 enzymatic activity in response to GGPP stimulation (fig. 14B), confirming that these sites are critical for the binding of FBP1 and GGPP. FIG. 14 is a graph showing that mutations in the GGPP binding site of human FBP1 protein of the invention inhibit the activity of FBP1 enzyme in response to GGPP stimulation; ggpp binding site mutations do not affect FBP1 homotetramer formation; GGPP binding site mutations inhibit FBP1 enzymatic activity in response to GGPP stimulation.
6 GGPP and FBP1 combined to regulate the occurrence and development of hepatocellular carcinoma
In view of the important regulatory role of GGPP on the activity of FBP1 and the important function of FBP1 itself as a tumor suppressor, the invention researches the role of GGPP and FBP1 in the process of inhibiting the occurrence and development of mouse hepatocellular carcinoma. The results show that wild-type mice develop liver cancer when a mouse primary hepatocellular carcinoma model is made using high fat diet and chemical mutagenesis (fig. 15A-B); and the re-supplementation of GGOH to hepatoma-modeled mice can obviously inhibit the generation and development of liver cancer of the mice (FIGS. 15C-E). FIG. 15 is a graph showing that GGOH of the present invention can reverse the occurrence and development of hepatocellular carcinoma in mice; A. high fat diet and chemical mutagenesis to make a time line of mouse primary hepatocellular carcinoma model; B. normal control group, high fat diet and chemical mutagenesis mice primary hepatocellular carcinoma group and reversal after GGOH anaplerosis; the degree of malignancy of hepatocellular carcinoma in three groups of mice in C-E.B was compared and statistical analysis of the number and volume of tumors was performed.
Similarly, in the hepatoma cell lines Huh7 and HepG2, GGPP treatment could also significantly inhibit the viability and proliferation of hepatoma cells (fig. 16). There was no significant change in the viability of both cells when they were transformed into FBP1-WT and FBP1-R50N in Huh7 or HepG 2; while the combination of both FBP1-WT and FBP1-R50N with GGPP treatment significantly decreased the FBP1-WT/GGPP group compared to FBP1-R50N/GGPP, indicating that the FBP1-R50 site is critical for its response to GGPP stimulation (FIG. 13). FIG. 16 is a graph showing that GGPP treatment of the present invention significantly inhibited the viability and proliferation of hepatoma cells; GGPP treatment obviously inhibits the activity and proliferation of liver cancer cells Huh 7; GGPP treatment obviously inhibits the activity and proliferation of liver cancer cells HepG 2. FIG. 13 is a graph showing that mutations at FBP1-R50 inhibit the activity of FBP1 in inhibiting hepatoma cells in response to GGPP stimulation; r50 reduces the ability of FBP1 to inhibit the viability and proliferation of hepatoma cells Huh7 in response to GGPP stimulation; the mutation of C-D.R50 reduces the ability of FBP1 to inhibit the viability and proliferation of hepatoma cells HepG2 in response to GGPP stimulation.
The foregoing shows and describes the general principles, essential features, and advantages of the invention. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, which are described in the foregoing description only for the purpose of illustrating the principles of the present invention, but that various changes and modifications may be made therein without departing from the spirit and scope of the invention as defined by the appended claims, specification, and equivalents thereof.
Claims (6)
1. The application of geranylgeranyl pyrophosphate GGPP (GGPP) in combination and allosteric activation of human fructose-1, 6-diphosphatase 1FBP1 in preparation of anti-hepatocellular carcinoma drugs is characterized in that: the chemical formula of GGPP is shown as the formula (I):
the amino acid sequence of the human FBP1 protein is shown in SEQ ID No. 1.
2. Use according to claim 1, characterized in that: the geranylgeranyl pyrophosphate GGPP is specifically combined with FBP1 and up-regulates the enzyme activity of FBP1 to promote gluconeogenesis and inhibit the migration of liver parenchyma cells and liver cancer cells.
3. Use according to claim 2, characterized in that: the geranylgeranyl pyrophosphate GGPP is coupled with glycolipid metabolic balance by sensitizing a target protein FBP1 of the geranylgeranyl pyrophosphate GGPP so as to regulate a molecular mechanism for the occurrence and development of hepatocellular carcinoma, and can be applied to the treatment of hepatocellular carcinoma.
4. Use according to claim 3, characterized in that: synthesizing a GGPP probe with a Biotin label, enriching GGPP binding protein in primary liver parenchymal cells of a mouse by using a Biotin-streptavidin affinity purification system, and performing mass spectrometry to screen out a plurality of GGPP potential target proteins related to glycolipid metabolism, fructose-1, 6-diphosphatase 1 in a gluconeogenesis pathway, liver pyruvate kinase in a glycolysis pathway and carnitine palmitoyltransferase 1 involved in lipid oxidation.
5. Use according to claim 1 or 4, characterized in that: the GGPP is specifically combined with FBP1 and up-regulates the enzyme activity of FBP1 to promote gluconeogenesis and reverse the Warburg effect of tumors so as to inhibit the occurrence and development of various tumors.
6. Use according to claim 1 or 4, characterized in that: the anti-tumor drug is an anti-hepatocellular carcinoma drug.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110999973.0A CN113694072A (en) | 2021-08-27 | 2021-08-27 | Application of GGPP (gas-gas phase plasma) combination and allosteric activation of humanized FBP1 in preparation of anti-hepatocellular carcinoma drugs |
| CN202111567012.9A CN113975285A (en) | 2021-08-27 | 2021-12-20 | Application of GGPP (gas-gas phase plasma) combination and allosteric activation of humanized FBP1 in preparation of anti-hepatocellular carcinoma drugs |
| PCT/CN2021/139760 WO2023024351A1 (en) | 2021-08-27 | 2021-12-20 | Use of ggpp binding and allosteric activation of human fbp1 in preparation of anti-hepatocellular carcinoma drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110999973.0A CN113694072A (en) | 2021-08-27 | 2021-08-27 | Application of GGPP (gas-gas phase plasma) combination and allosteric activation of humanized FBP1 in preparation of anti-hepatocellular carcinoma drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113694072A true CN113694072A (en) | 2021-11-26 |
Family
ID=78656405
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110999973.0A Pending CN113694072A (en) | 2021-08-27 | 2021-08-27 | Application of GGPP (gas-gas phase plasma) combination and allosteric activation of humanized FBP1 in preparation of anti-hepatocellular carcinoma drugs |
| CN202111567012.9A Pending CN113975285A (en) | 2021-08-27 | 2021-12-20 | Application of GGPP (gas-gas phase plasma) combination and allosteric activation of humanized FBP1 in preparation of anti-hepatocellular carcinoma drugs |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111567012.9A Pending CN113975285A (en) | 2021-08-27 | 2021-12-20 | Application of GGPP (gas-gas phase plasma) combination and allosteric activation of humanized FBP1 in preparation of anti-hepatocellular carcinoma drugs |
Country Status (2)
| Country | Link |
|---|---|
| CN (2) | CN113694072A (en) |
| WO (1) | WO2023024351A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023024351A1 (en) * | 2021-08-27 | 2023-03-02 | 南京大学 | Use of ggpp binding and allosteric activation of human fbp1 in preparation of anti-hepatocellular carcinoma drug |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2387734A1 (en) * | 1999-10-18 | 2001-04-26 | Washington State University Research Foundation | Geranyl diphosphate synthase large subunit, and methods of use |
| WO2005007090A2 (en) * | 2003-07-03 | 2005-01-27 | President And Fellows Of Harvard College | Inhibitors of the map kinase pathway |
| US20130281493A1 (en) * | 2010-10-07 | 2013-10-24 | The Trustees Of The University Of Columbia In The City Of New York | Method for Treating Cancer Harboring a p53 Mutation |
| BR112021000145A2 (en) * | 2018-07-09 | 2021-04-06 | Flagship Pioneering Innovations V, Inc | FUSOSOME COMPOSITIONS AND USES OF THE SAME |
| CN113694072A (en) * | 2021-08-27 | 2021-11-26 | 南京大学 | Application of GGPP (gas-gas phase plasma) combination and allosteric activation of humanized FBP1 in preparation of anti-hepatocellular carcinoma drugs |
-
2021
- 2021-08-27 CN CN202110999973.0A patent/CN113694072A/en active Pending
- 2021-12-20 WO PCT/CN2021/139760 patent/WO2023024351A1/en unknown
- 2021-12-20 CN CN202111567012.9A patent/CN113975285A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023024351A1 (en) * | 2021-08-27 | 2023-03-02 | 南京大学 | Use of ggpp binding and allosteric activation of human fbp1 in preparation of anti-hepatocellular carcinoma drug |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113975285A (en) | 2022-01-28 |
| WO2023024351A1 (en) | 2023-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | Targeting stromal glutamine synthetase in tumors disrupts tumor microenvironment-regulated cancer cell growth | |
| Benjamin et al. | Global profiling strategies for mapping dysregulated metabolic pathways in cancer | |
| Torresano et al. | Metabolic reprogramming and disease progression in cancer patients | |
| Song et al. | RNA editing mediates the functional switch of COPA in a novel mechanism of hepatocarcinogenesis | |
| CA2530789A1 (en) | Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol | |
| CN108603884A (en) | The method for being enriched with acellular nucleosome | |
| Feng et al. | SLC6A8 is involved in the progression of non-small cell lung cancer through the Notch signaling pathway | |
| Zhang et al. | Down-regulation of ACACA suppresses the malignant progression of Prostate Cancer through inhibiting mitochondrial potential | |
| CN113975285A (en) | Application of GGPP (gas-gas phase plasma) combination and allosteric activation of humanized FBP1 in preparation of anti-hepatocellular carcinoma drugs | |
| Chen et al. | STEAP4 and insulin resistance | |
| Xu et al. | Hepatic CDP-diacylglycerol synthase 2 deficiency causes mitochondrial dysfunction and promotes rapid progression of NASH and fibrosis | |
| Link-Lenczowski et al. | A switch of N-glycosylation of proteome and secretome during differentiation of intestinal epithelial cells | |
| Wang et al. | Metabolomics study of the metabolic changes in hepatoblastoma cells in response to NTCP/SLC10A1 overexpression | |
| Li et al. | METTL7B serves as a prognostic biomarker and promotes metastasis of lung adenocarcinoma cells | |
| Luo et al. | Dissection of cellular and molecular mechanisms of aristolochic acid-induced hepatotoxicity via single-cell transcriptomics | |
| Hong et al. | Single-cell transcriptional profiling reveals heterogeneity and developmental trajectories of Ewing sarcoma | |
| Hung et al. | Molecular alterations and heterogeneity in hepatocellular carcinoma | |
| Chen et al. | Erchen decoction to reduce oxidative stress in dyslipidemia phlegm-dampness retention syndrome mice: in vivo mechanism revealed by metabolomics (liquid chromatography–mass spectrometry) | |
| Lin et al. | Metabolomic biomarkers for the diagnosis and post-transplant outcomes of AFP negative hepatocellular carcinoma | |
| Clifford et al. | Dominant negative signal transducer and activator of transcription 2 (STAT2) protein: stable expression blocks interferon α action in skin squamous cell carcinoma cells | |
| KR102167739B1 (en) | Method, composition and kit for screening ALK or ROS-1 kinase inhibitor | |
| Wang et al. | Q-marker identification of Paris polyphylla var. yunnanensis (Franch.) Hand.-Mazz. in pulmonary metastasis of liver cancer mice | |
| Liao et al. | A comparative study on the incidence, aggravation, and remission of lupus nephritis based on iTRAQ technology | |
| CN117683893B (en) | Biomarker for predicting drug resistance of BTK inhibitor and application thereof | |
| Chen et al. | Effect of the genetic mutant G71R in uridine diphosphate-glucuronosyltransferase 1A1 on the conjugation of bilirubin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211126 |
|
| WD01 | Invention patent application deemed withdrawn after publication |